Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ: 001540)
South Korea
· Delayed Price · Currency is KRW 6,650.00
-90.00 (-1.34%)
Dec 20, 2024, 9:00 AM KST
Ahn-Gook Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 14,281 | 1,290 | 6,875 | 3,939 | -1,315 | 2,536 | Upgrade
|
| Depreciation & Amortization | 6,799 | 5,023 | 4,930 | 4,507 | 4,683 | 3,854 | Upgrade
|
| Loss (Gain) From Sale of Assets | -13,928 | -17.13 | -28.25 | -138.65 | 60.42 | -24.51 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 37.78 | - | - | 1,462 | Upgrade
|
| Loss (Gain) From Sale of Investments | -418.92 | -920.69 | 889.36 | -2,033 | -625.7 | -275.75 | Upgrade
|
| Loss (Gain) on Equity Investments | -379.36 | 1,641 | 1,645 | -2,613 | -1,780 | -1,134 | Upgrade
|
| Provision & Write-off of Bad Debts | -207.02 | 757.97 | 129.7 | 171.68 | 1,025 | 871.7 | Upgrade
|
| Other Operating Activities | 10,987 | 4,747 | 5,478 | 8,724 | 5,462 | 1,805 | Upgrade
|
| Change in Accounts Receivable | -371.29 | -7,972 | -11,980 | -10,171 | 8,940 | 19,141 | Upgrade
|
| Change in Inventory | -10,521 | -12,861 | -4,497 | -3,969 | -1,260 | -1,731 | Upgrade
|
| Change in Accounts Payable | -2,757 | 2,569 | 2,528 | 1,090 | -1,506 | -2,259 | Upgrade
|
| Change in Other Net Operating Assets | 3,875 | 4,415 | -4,219 | 1,964 | -2,493 | -2,166 | Upgrade
|
| Operating Cash Flow | 7,359 | -1,328 | 1,788 | 1,472 | 11,190 | 22,078 | Upgrade
|
| Operating Cash Flow Growth | - | - | 21.49% | -86.84% | -49.32% | - | Upgrade
|
| Capital Expenditures | -76,805 | -5,474 | -2,931 | -4,035 | -24,119 | -3,738 | Upgrade
|
| Sale of Property, Plant & Equipment | 22,867 | 11,201 | 15.5 | 42.09 | 26.98 | 409.61 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | -1,476 | Upgrade
|
| Sale (Purchase) of Intangibles | -509.55 | -708.77 | -735.39 | -1,028 | -354.78 | -0.48 | Upgrade
|
| Investment in Securities | 8,948 | 12,167 | 9,960 | 4,931 | 15,021 | -22,789 | Upgrade
|
| Other Investing Activities | - | 0 | -0 | 62.75 | - | - | Upgrade
|
| Investing Cash Flow | -45,499 | 17,186 | 6,431 | 3,118 | -9,426 | -27,594 | Upgrade
|
| Long-Term Debt Issued | - | 10,000 | - | - | 2,500 | 12,300 | Upgrade
|
| Long-Term Debt Repaid | - | -12,593 | -662.99 | -889.69 | -11,439 | -4,371 | Upgrade
|
| Net Debt Issued (Repaid) | 56,642 | -2,593 | -662.99 | -889.69 | -8,939 | 7,929 | Upgrade
|
| Repurchase of Common Stock | - | - | -554 | -435.14 | - | - | Upgrade
|
| Dividends Paid | -2,500 | -2,500 | -2,511 | -2,521 | -2,521 | -2,521 | Upgrade
|
| Other Financing Activities | - | - | - | - | - | 1,247 | Upgrade
|
| Financing Cash Flow | 54,142 | -5,093 | -3,728 | -3,846 | -11,460 | 6,655 | Upgrade
|
| Foreign Exchange Rate Adjustments | -4.84 | 8.08 | 77.69 | 136.61 | -281.98 | 134.88 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | - | - | - | - | Upgrade
|
| Net Cash Flow | 15,997 | 10,772 | 4,569 | 881.42 | -9,978 | 1,274 | Upgrade
|
| Free Cash Flow | -69,445 | -6,802 | -1,143 | -2,563 | -12,929 | 18,340 | Upgrade
|
| Free Cash Flow Margin | -26.24% | -2.91% | -0.56% | -1.57% | -9.02% | 11.77% | Upgrade
|
| Free Cash Flow Per Share | -6110.23 | -598.47 | -100.41 | -223.77 | -1022.23 | 1600.47 | Upgrade
|
| Cash Interest Paid | 2,092 | 976.99 | 662.47 | 121.11 | 414.62 | -315.57 | Upgrade
|
| Cash Income Tax Paid | 2,196 | 2,921 | 713.85 | 101.29 | 3,301 | 1,384 | Upgrade
|
| Levered Free Cash Flow | -68,654 | 4,491 | 1,732 | -988.07 | -12,257 | 17,516 | Upgrade
|
| Unlevered Free Cash Flow | -67,271 | 4,581 | 1,832 | -915.05 | -11,784 | 18,163 | Upgrade
|
| Change in Net Working Capital | 583.72 | -2,577 | 5,295 | -317.8 | -8,037 | -16,537 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.